Adjuvant treatment
The treatment that is given after surgery to kill any remaining cancer cells and lower your risk of the cancer returning. The goal of adjuvant treatment is to keep you cancer-free for as long as possible.
Chemotherapy
A type of medication that kills cells that grow and divide rapidly, including cancer cells and normal cells.
Cycle
A cycle is a course of treatment that is repeated on a regular schedule with periods of rest in between.
HER2 status
HER2 stands for human epidermal growth factor receptor 2. HER2 is a type of protein found on the surface of cells in everyone that tells the cells to grow and divide. When breast cancer cells have too many HER2 receptors, they are called HER2-positive (HER2+).
Inflammatory
When the breast is swollen, red, or inflamed as a result of the cancer cells blocking lymph vessels.
Infusion
A method of putting fluids, including drugs, into the bloodstream. Also called intravenous infusion.
Lymph nodes
Small, bean-shaped organs found throughout the body that store white blood cells and help remove cell waste, germs, and other harmful substances from the body.
Node positive
This means your doctor has detected cancer cells in one or more of your lymph nodes.
Nodal status
Cancer cells can sometimes appear in nearby structures known as "lymph nodes." When cancer cells appear in one or more lymph nodes, the cancer is said to be "node-positive" (node+).
Neoadjuvant treatment
Treatment given before surgery to help reduce or get rid of cancer cells before surgery.
Pathologic complete response (pCR)
A pCR means that no cancer cells were found in the tissue removed during surgery. A pCR is not the same as a cure.
Port
A surgically implanted disc through which blood can be taken and medication can be given without repeated needle sticks
Residual disease
If cancer cells are found in the tissue removed during surgery, it is known as residual disease.
Targeted therapies
Designed to target specific characteristics of cancer cells. Targeted treatments may also affect normal cells
Tumor size
The size of the tumor is how large it is at its widest point.
Hormone receptor status
Two hormones naturally made by the body are called estrogen and progesterone. These hormones attach to hormone receptors on cells. Some tumors have hormone receptors—they can have estrogen receptors, progesterone receptors, or both. This is called “hormone receptor-positive” breast cancer. “Hormone receptor-negative” breast cancer is when the cancer cells do not have hormone receptors.
Hyaluronidase
Hyaluronidase is a protein naturally found in most tissues of the body and helps enhance the way the body absorbs medicines injected under the skin. When PHESGO is injected, the hyaluronidase makes the tissue under the skin more absorbent temporarily so that it’s able to receive the medication.
Locally advanced
Cancer that has spread from where it started to nearby tissue or lymph nodes.
Early-stage breast cancer
Breast cancer that has not spread beyond the breast or the axillary lymph nodes.
HER2-targeted therapies
A type of targeted cancer treatment that binds to HER2 receptors to fight cancer cells that have too many HER2 receptors.
Surgery
The medical practice of treating injuries or disease by cutting into the body to physically remove tissue.
What does PERJETA treat?
PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin® (trastuzumab) and chemotherapy for:
Important Safety Information
Side effects may vary based on chemotherapy regimen.
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Talk to a healthcare professional for more information about the benefits and risks of PERJETA.
Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
What does PHESGO treat?
PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for:
Important Safety Information
What are the most common side effects?
The most common side effects of PHESGO when given with chemotherapy as part of an early breast cancer regimen are:
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Talk to a healthcare professional for more information about the benefits and risks of PHESGO.
Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
Who is KADCYLA for?
Early Breast Cancer
KADCYLA is a prescription medicine used as an adjuvant (after surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (before surgery) treatment including taxane and trastuzumab (Herceptin®) and there is cancer remaining in the tissue removed during surgery. Patients are selected for therapy based on an FDA-approved test for KADCYLA.
Important Safety Information
What is the most Important Safety Information I should know about KADCYLA?
Liver problems
Heart problems
Pregnancy
Contact your doctor right away if you experience symptoms associated with these side effects.
What are the additional possible serious side effects of KADCYLA?
Lung problems
Infusion-related reactions
Serious bleeding
Low platelet count
Nerve damage
Skin reactions around the infusion site
What are the most common side effects of KADCYLA?
The most common side effects in people taking KADCYLA for early breast cancer are:
You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-2555. You may contact the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
Talk to a healthcare professional for more information about the benefits and risks of KADCYLA.
Please see full Prescribing Information for Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
What does PERJETA treat?
PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin® (trastuzumab) and chemotherapy for:
Important Safety Information
Side effects may vary based on chemotherapy regimen.
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Talk to a healthcare professional for more information about the benefits and risks of PERJETA.
Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.